Clinical Trial Update: A Study in India on the Immune Response and Safety of a Respiratory Syncytial Virus (RSV) Older Adults (OA) Vaccine When Given to Older Adults 60 Years of Age and Above and Adults 50-59 Years of Age at Increased Risk (AIR) of Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV-LRTD) [Phase 3]

View source ↗

Summary

Phase 3 study assessing immune response and safety of the RSV vaccine Arexvy in adults aged 50-59 at increased risk and 60 years and older; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Arexvy

Snippet

Sponsor: GlaxoSmithKline | Conditions: Respiratory Syncytial Virus Infections | Phase 3 | Status: COMPLETED